Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Cyclosporin

Phase 2Small molecule

Cyclosporin is one of 57 small molecule programs targeting Ischemia. It is currently in Phase 2.

2

Indications

18

Total Trials

4

Active Trials

56

Competitors

Pipeline

Status by Indication[3][1]

Indication

IschemiaActive, not recruiting

Membranous NephropathyNot yet recruiting

IschemiaPreclinical

Active, not recruiting

Membranous NephropathyPhase 2

Not yet recruiting

Competition

Competitive Landscape

45 competitors in Ischemia

#DrugCompanyPhaseTrials

Crestor

Corlanor

Lovenox

Repatha

Bayer Aspirin

Remodulin

United Therapeutics

Taxol

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Persantine

Boehringer Ingelheim

Heparin Sodium

BBaxter Healthcare Corporation

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2/3Recruiting

Membranous Nephropathy

NCT06470191

Q4 2027

Post-ApprovalRecruiting

Alopecia Areata

NCT07381556

Phase 2Recruiting

Type 1 Diabetes

NCT05153070

Q1 2029

Phase 2Not yet recruiting

Membranous Nephropathy

NCT07029139

Clinical

Trials by Indication[1]

Membranous Nephropathy2 trials

A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.

Recruiting·SShanghai Jiaolian Drug Research and Development Co., Ltd·Phase 2/3·NCT06470191·216 enrolled

A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 2·NCT07029139·156 enrolled

Ischemia1 trial

Effect of Cyclosporine and Remote Ischemic Preconditioning in Reperfusion Ischemia Injury on Tetralogy Fallot Patients With Correction Surgery

Completed·IIndonesia University·N/A·NCT05691764·40 enrolled

Bone Marrow Transplantation1 trial

Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00705120·9 enrolled

Histiocytosis1 trial

Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004

Completed·KKarolinska University Hospital·Phase 3·NCT00426101·368 enrolled

Sjögren Syndrome1 trial

Effect of Ciclosporin Eyedrops on Sjögren Syndrome

Completed·HHospital Hietzing·N/A·NCT04597762·12 enrolled

12 more indications

Membranoproliferative Glomerulonephritis1 trial

Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis

Unknown status·—·Phase 3·NCT03180723·30 enrolled

Kidney Transplant1 trial

Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)

Completed·SStanford University·Phase 4·NCT00296296·29 enrolled

Eye Disease1 trial

Pilot Study of a Homeopathic Therapy in Combination With Cyclosporin (Restasis) in the Treatment of Dry Eye Disease

Terminated·UUniversity of Missouri-Columbia·Phase 2·NCT01072526·7 enrolled

Liver Transplant1 trial

Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C

Completed· Novartis logo

Novartis·Phase 4·NCT00938860·92 enrolled

Alopecia Areata1 trial

Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study

Recruiting·EErasmus Medical Center·Phase 4·NCT07381556·50 enrolled

Psoriasis1 trial

Combined Use of Cyclosporine and Metformin in Treatment of Psoriasis vs Cyclosporine Alone

Completed·—·Phase 1·NCT07375654·32 enrolled

Tacrolimus1 trial

Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04788641·62 enrolled

Lymphoma1 trial

Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma

Terminated·EEastern Cooperative Oncology Group·Phase 2·NCT00057954·6 enrolled

Stem Cell Transplantation1 trial

Stem Cell Transplantation for Metastatic Solid Tumors

Terminated·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00001880·42 enrolled

Glomerulosclerosis, Focal1 trial

Focal Segmental Glomerulosclerosis Clinical Trial

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00135811·192 enrolled

Type 1 Diabetes1 trial

Clinical and Biological Responses to Repeated Administration of Low-dose Interleukin-2 in Patients With Type 1 Diabetes and a Residual Insulin Secretion

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT05153070·24 enrolled

Dry Eye Disease (DED)1 trial

A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study

Completed·LLaboratoires Thea··NCT07234318·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Cyclosporin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cyclosporin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cyclosporin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

Related News